Shenzhen Weize Technology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Shenzhen Weize Technology Co., Ltd. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 2 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ELESTRENY. The owner is based in Shenzhen.
Centre,Fukang Comm., Longhua St.,Longhua
Rm.212,210,208,2F,A2#,Demei Industrial
Shenzhen 518109 , CN
Showing of trademarks Trademarks
Trademark Classifications
Shenzhen Weize Technology Co., Ltd.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Shenzhen Weize Technology Co., Ltd. have?
Shenzhen Weize Technology Co., Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned.
What trademark classes does Shenzhen Weize Technology Co., Ltd. file in?
Shenzhen Weize Technology Co., Ltd. files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 20 (Furniture). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Shenzhen Weize Technology Co., Ltd.'s most well-known trademarks?
Shenzhen Weize Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as ELESTRENY. These are among 1 currently registered trademark in the portfolio.
What is Shenzhen Weize Technology Co., Ltd.'s trademark registration success rate?
Shenzhen Weize Technology Co., Ltd. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.